ABOS Stock — Acumen Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.22

Market cap

$16.2M

Cash

$78.6M

Enterprise value

-$36.1M

Balance sheet

Cash	$78.6M
Debt	$26.3M
Net cash	$52.3M
Enterprise value	-$36.1M
Basic shares	72.3M shares
Fully diluted shares	95.5M shares
Fully diluted market cap	$21.0M
Cash per share	$1.09
Quarterly burn	$18.1M
Cash runway	6.1 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

72.3M

Pre-funded warrants

0.0M

Options

15.4M

RSUs

3.1M

Warrants

0.7M

Converts

1.0M

Conv preferred

0.0M

ESPP reserve

3.0M

FDSO

95.5M

Cap table as of 2026-06-30.

Price history

Loading ABOS daily closes…

Loading price history…

Recently reported

sabirnetug Phase 2 Missed primary · 2026-10-30

ALTITUDE-AD · alzheimer disease

Source release →

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

sabirnetug

Phase 2 · Active Modality: monoclonal antibody (IgG2)

Aliases ACU193

Target amyloid-beta oligomers (AβOs)

Partnerships Halozyme, Inc.: non-exclusive license to Halozyme drug-delivery technology for a subcutaneous formulation of sabirnetug (seven-figure upfront paid Jan 2024; development/commercial milestones; single-digit royalties on worldwide net sales); Lonza Sales AG: non-exclusive manufacturing license (glutamine synthetase expression system), 1.0M CHF upfront, <1% to low-single-digit royalties

Indications

Alzheimer's disease (early AD: mild cognitive impairment or mild dementia due to AD) (Phase 2)

Catalysts

— late 2026

Status note Sole clinical-stage product candidate. FDA granted Fast Track designation to ACU193 in October 2022. Phase 1 subcutaneous formulation study in healthy volunteers completed March 2025; supports further development as more convenient dosing option.

ACU301

Preclinical · Active

Target amyloid-beta oligomers (AβOs)

Partnerships JCR Pharmaceuticals: collaboration, option and license agreement for Aβ oligomer-targeted EBD candidates (upfront paid 2025; $9.25M option exercise paid June 2026; up to $40M development + $515M sales milestones; single-digit royalties)

Indications

Alzheimer's disease (Preclinical)

Catalysts

— mid-2027

Status note One of two EBD (Enhanced Brain Delivery) development candidates nominated June 2026 and licensed under the JCR collaboration. Preclinical data reported March 2026.

ACU401

Preclinical · Active

Target amyloid-beta oligomers (AβOs)

Partnerships JCR Pharmaceuticals: collaboration, option and license agreement for Aβ oligomer-targeted EBD candidates (upfront paid 2025; $9.25M option exercise paid June 2026; up to $40M development + $515M sales milestones; single-digit royalties)

Indications

Alzheimer's disease (Preclinical)

Catalysts

— mid-2027

Status note One of two EBD (Enhanced Brain Delivery) development candidates nominated June 2026 and licensed under the JCR collaboration. Preclinical data reported March 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	sabirnetug
Lead indication	Alzheimer Disease
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06335173	Phase 2	Active, not recruiting	Sponsor	Acumen Pharmaceuticals	—	Alzheimer Disease	late 2026 Est. Nov 7, 2026 · guidance midpoint

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Acumen Pharmaceuticals on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	20,992,669	no change	0.49%	2026-08-14
ADAR1 Capital Management	2,111,334	-45,000	0.26%	2026-08-14
Ikarian Capital	1,053,797	no change	0.46%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ABOS — Acumen Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ABOS — Acumen Pharmaceuticals Inc.